Cancer Research and Treatment

Case Report

Molecular and Treatment Characteristics of SMARCB1 or SMARCA4-Deficient Undifferentiated Tumor: Retrospective Case Series: Hyeon Gyu Kang, Jiwon Koh, Tae Min Kim, Doo Hee Han, Tae-Bin Won, Dong-Wan Kim, Dong-Young Kim, Bhumsuk Keam; Cancer Res Treat. 2024;56(3):967-971. Published online February 13, 2024; DOI: https://doi.org/10.4143/crt.2023.1308

SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor has aggressive nature with a poor prognosis. Patients with this disease were diagnosed by immunohistochemistry or next-generation sequencing. Those who were able to receive a surgery tended to be cured, while the others treated with chemotherapy, radiation therapy, or immune checkpoint inhibitor were often insensitive to these therapies. However, one having CD274 (PD-L1) amplification showed the response to immune checkpoint inhibitor and a good prognosis. We believed that this report could provide promising information for determining the optimal treatment option.

Citations

Citations to this article as recorded by

Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma
Ben Jin, Hao Hu, Yanhua Lu, Xia Tian, Guanghui Hu, Jingjing Xu, Xingqi Wu, Long Zhang, Juxiang Chen, Miaoxia He
Acta Neuropathologica Communications.2026;[Epub] CrossRef
Successful Multimodal Treatment of SMARCA4-Deficient Sinonasal Carcinoma
Eisuke Ishigami, Masayoshi Kobayashi, Hiroyuki Morishita, Takaki Miwa, Shizuka Saeki, Sohsuke Yamada
Ear, Nose & Throat Journal.2026;[Epub] CrossRef

5,425 View
212 Download
1 Web of Science
2 Crossref

First
Prev
Page of 1
Next
Last

Search